NasdaqHealth CarePharmaceutical PreparationsSEATTLE, WA

Atossa Therapeutics, Inc. ATOS

Ask your AI

Estimated market cap $19.56M9.98M shares, shares as of Jul 31, 2026CIK 1488039

Insider trades, 12 mo

—

No open-market trades

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

8.8% of shares · 4 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in Atossa Therapeutics, Inc.'s latest quarterly report, compared with the one before.

Filed Nov 10, 2026 · Quarter ended Sep 30, 2026

Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in Atossa Therapeutics, Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since May 21, 2025. Insiders have two business days to file.

Recent insider trades

Steven C. Quay President & CEO, Director	May 21, 2025 Form 4 ↗	Buy	+$9,890 11,239 sh @ $0.88	-114.4%
H. Lawrence Remmel Director	Mar 26, 2025 Form 4 ↗	Buy	+$7,000 10,000 sh @ $0.70	-113.9%

All ATOS insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

881,557 shares

26 funds report ATOS. Values checked against market prices.

Funds own 13% of shares (Q2 2026)

32 funds hold the stock.

Q3 2026: 8.8% · 5,560 of ~8,900 funds reported so far

Q2 2025<0.1%
Q4 2025<0.1%
Q1 202614%
Q2 202613%
Q3 2026 (so far)8.8%

Q3 2026. 6 new, 4 added to, 2 trimmed, 13 exited since Q2 2026.

Top 13F holders
#
1	Vanguard Capital Management LLC 13F ↗	361,747	$705.4K	unchanged
2	BlackRock, Inc. 13F ↗	168,621	$328.8K	+2.6%
3	Renaissance Technologies LLC 13F ↗	109,907	$214.3K	-16.8%
4	Geode Capital Management, LLC 13F ↗	95,577	$186.4K	+3.5%
5	Vanguard Fiduciary Trust Co 13F ↗	52,583	$102.5K	unchanged
6	State Street Corp 13F ↗	39,761	$77.5K	unchanged
7	UBS Group AG 13F ↗	30,508	$59.5K	-63.1%
8	Morgan Stanley 13F ↗	12,345	$24.1K	unchanged
9	Vanguard Global Advisers, LLC 13F ↗	3,089	$6,024	unchanged
10	Barclays plc 13F ↗	2,558	$4,988	New

Download CSV Every fund that holds ATOS, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Recent congressional trades
Member	Transaction	Amount	Traded → disclosed	Since trade
Roger Marshall R House · KS	Purchase Dependent child	$1,001 - $15,000	Oct 25 → Aug 6 ↗ 285d late	—

All 1 trade →Free on every plan.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Atossa Therapeutics, Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Atossa Therapeutics, Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report, adjusted for splits

Funds holding the stock by quarter

Q2 2025	1	—	1	$12
Q4 2025	1	0	1,871	$16.6K
Q1 2026	34	+33	1.24M	$6.5M
Q2 2026	32	-2	1.35M	$2.6M
Q3 2026	26	-6	881,557	$1.7M

Each point is a quarter-end, from Q2 2025 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (04962H704). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q2 2025) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits (1-for-15 on Feb 2, 2026): reports from before a split are multiplied by its ratio, so every quarter is on the share count of Q3 2026.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakesNone in 12 mo 8-K events4 in 90 days Patents5 patents granted Short interestFINRA · updated Oct 15 Planned insider salesNone in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials2 active IPO history7 registrations Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: ATOSSA THERAPEUTICS, INC.
Address: 1448 NW MARKET STREET, SUITE 500, SEATTLE, WA 98107
Phone: 206.588.0256
Fiscal year ends: Dec 31
Filer category: Non-accelerated filer, smaller reporting company
Incorporated in: DE
Listed as: ATOS (Nasdaq)
Former names: ATOSSA GENETICS INC (until 2019)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$1.96+$0.02 (+1.03%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $1.94 · High $2.91Nov 13, 2026

Aug 13, 2026Low $1.90 · High $2.91Nov 13, 2026

Nov 13, 2025Low $1.75 · High $13.57Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. The stock split 1-for-15 on Feb 2, 2026; earlier prices are shown divided by the split ratio. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.